Valuation: Arcus Biosciences, Inc.

Market Cap 3.56B 3.11B 2.88B 2.66B 5.01B 342B 5.1B 34.33B 13.47B 168B 13.38B 13.09B 577B P/E 2026 *
-7.71x
P/E 2027 * -8.4x
Enterprise Value 2.94B 2.57B 2.38B 2.2B 4.13B 283B 4.21B 28.34B 11.12B 138B 11.05B 10.81B 476B EV / Sales 2026 *
34.6x
EV / Sales 2027 * 35.5x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.15%
1 week-7.40%
Current month-9.11%
1 month+15.88%
3 months+18.23%
6 months+28.59%
Current year+17.58%
1 week 27.21
Extreme 27.21
30.86
1 month 23.31
Extreme 23.31
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.84
Extreme 8.84
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Director/Board Member 62 10/12/2019
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Date Insider Type Main position Quantity % Market Cap.
07-10Sell

Founder

-20,067 0.0160%
06-24Sell

Founder

-6,431 0.0051%
06-11Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%-7.40%+210.30%+28.95% 3.56B
-0.02%+1.40%+3.09%+7.35% 50.35B
-1.72%-3.49%+384.40%+588.28% 39.32B
+1.25%+2.65%+32.67%-5.50% 34.69B
+1.99%+3.13%+15.43%+57.31% 34.08B
-1.31%-3.03%+2.51%+25.24% 26.63B
-0.05%-5.06% - - 16.49B
+0.19%+0.50%+70.97%+116.14% 15.31B
+1.39%+4.32%+16.03%+19.07% 13.8B
+0.67%+1.53%+15.40%-31.44% 12.87B
Average +0.13%-1.38%+83.42%+89.49% 24.71B
Weighted average by Cap. +0.15%-0.81%+83.49%+120.02%

Financials

2026 *2027 *
Net sales 85.06M 74.33M 68.72M 63.49M 120M 8.17B 122M 819M 322M 4B 320M 312M 13.78B 93.06M 81.32M 75.18M 69.46M 131M 8.94B 133M 897M 352M 4.38B 350M 342M 15.07B
Net income -456M -399M -369M -341M -641M -43.84B -653M -4.4B -1.73B -21.47B -1.71B -1.68B -73.91B -431M -376M -348M -321M -605M -41.35B -616M -4.15B -1.63B -20.25B -1.62B -1.58B -69.72B
Net Debt -621M -543M -502M -464M -873M -59.68B -889M -5.99B -2.35B -29.22B -2.33B -2.28B -101B -259M -227M -210M -194M -365M -24.91B -371M -2.5B -980M -12.2B -974M -953M -42B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
15/07/26 US$27.89 -1.55% 25,304
14/07/26 US$28.33 +0.93% 801,993
13/07/26 US$28.07 -2.94% 954,774
10/07/26 US$28.92 -3.47% 811,732
09/07/26 US$29.96 -0.99% 753,380
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.33USD
Average target price
35.75USD
Spread / Average Target
+26.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock